Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
Ipamorelin is a small research peptide that scientists study in the laboratory. A peptide is a short chain of amino acids, which are the tiny building blocks that make up proteins. This plain-language guide explains what Ipamorelin is, where it came from, and what published, preclinical research says about it. Everything below is for education only and describes Research Use Only (RUO) material, not a product for people or animals.
What is Ipamorelin?
Ipamorelin is a pentapeptide, which simply means a peptide built from five amino acids joined in a row. Researchers describe it as a growth hormone secretagogue. A growth hormone secretagogue is a molecule that, in laboratory and animal studies, can signal certain cells to release growth hormone.
Ipamorelin does this by acting as a ghrelin receptor agonist. The ghrelin receptor (also called GHS-R) is a docking point on the surface of some cells. An agonist is a molecule that fits into a receptor and switches it on, a bit like a key turning a lock. In published animal research, Ipamorelin was noted for being fairly selective, meaning it mainly acted at this one receptor pathway.
Where does Ipamorelin come from?
Ipamorelin was first described in the late 1990s by a research group led by K. Raun and colleagues, working with scientists connected to the Danish company Novo Nordisk. Their 1998 paper in the European Journal of Endocrinology called Ipamorelin the first selective growth hormone secretagogue of its kind.
Because it is made in a lab rather than taken from a plant or animal, Ipamorelin is a synthetic peptide. Chemists build it one amino acid at a time using a method called solid-phase peptide synthesis, then purify and test the result. It belongs to a family of lab-made compounds that scientists use to study how the ghrelin receptor and growth hormone signaling work.
What does the research say about Ipamorelin?
The research on Ipamorelin is preclinical, meaning it comes from cell and animal studies rather than approved human treatments. Findings should always be tied to the study that reported them.
In the 1998 study by Raun and colleagues, Ipamorelin increased growth hormone release in animal models and was described as selective for that effect. In a later rat study (Svensson and colleagues, Journal of Endocrinology, 1999), researchers reported that Ipamorelin was associated with longitudinal bone growth in young rats under the conditions they tested.
These are observations from specific animal experiments. They do not show what Ipamorelin does in humans, and they are not evidence of any health benefit. Reading the original papers is the best way to understand exactly what each research team measured and concluded.
Is Ipamorelin FDA approved or banned in sport?
Ipamorelin is not approved by the U.S. Food and Drug Administration for treating any condition. It is not an approved medicine. Suppliers offer it as a Research Use Only chemical, not for human or veterinary use.
In sport, the World Anti-Doping Agency (WADA) lists growth hormone secretagogues among prohibited substances on its Prohibited List. Because Ipamorelin acts as a growth hormone secretagogue and ghrelin receptor agonist, it falls in a category that WADA prohibits for athletes at all times. This is a plain regulatory fact, not advice.
How researchers store and handle Ipamorelin
In a laboratory setting, peptides like Ipamorelin are handled as sensitive research chemicals. Freeze-dried peptide powder is generally kept cold, sealed, and away from light and moisture to help keep it stable over time. Labels, lot numbers, and safety records help researchers keep track of each vial.
Careful handling is about keeping a research material intact and identifiable, not about any use in a body. This guide does not give directions for preparing or applying Ipamorelin, because it is not intended for human or animal use.
Ipamorelin vs CJC-1295
Ipamorelin and CJC-1295 are both studied in growth hormone research, but they work through different pathways. Ipamorelin acts at the ghrelin receptor as a growth hormone secretagogue. CJC-1295 is studied as a growth-hormone-releasing hormone (GHRH) analog, meaning it mimics a natural signaling molecule that acts on a separate receptor.
Because they target different receptors, scientists sometimes discuss them together when studying how growth hormone signaling is regulated. Comparing their mechanisms is a research topic, not a suggestion to combine or use either one.
Ipamorelin research materials at Dissolv Labs
Dissolv Labs offers the following as Research Use Only reference materials for laboratory study:
Frequently asked questions
What does growth hormone secretagogue mean?
It means a molecule that can prompt cells to release growth hormone. Ipamorelin is studied as this kind of molecule in preclinical research, acting through the ghrelin receptor.
Is Ipamorelin a steroid?
No. Ipamorelin is a peptide, a short chain of amino acids. Steroids are a different type of molecule with a different chemical structure.
Is Ipamorelin legal to buy?
Ipamorelin is sold as a Research Use Only chemical, not as a medicine or supplement. It is not FDA approved for human use, and it is prohibited in sport by WADA. Rules can vary by place, so researchers follow the laws that apply to them.
Who discovered Ipamorelin?
It was first described by K. Raun and colleagues in a 1998 paper, with researchers connected to Novo Nordisk.
The bottom line
Ipamorelin is a five-amino-acid research peptide studied as a selective growth hormone secretagogue and ghrelin receptor agonist. Preclinical animal studies, such as those by Raun and Svensson and colleagues, looked at how it affects growth hormone release and bone growth in animals. It is not FDA approved, it is prohibited in sport by WADA, and it is sold for Research Use Only, not for human or animal use.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998 (PubMed).
- Svensson J, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Journal of Endocrinology, 1999 (PubMed).
- World Anti-Doping Agency. The Prohibited List.
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
